Clinical review: Vasopressin and terlipressin in septic shock patients
- PMID: 15774080
- PMCID: PMC1175907
- DOI: 10.1186/cc2945
Clinical review: Vasopressin and terlipressin in septic shock patients
Abstract
Vasopressin (antidiuretic hormone) is emerging as a potentially major advance in the treatment of septic shock. Terlipressin (tricyl-lysine-vasopressin) is the synthetic, long-acting analogue of vasopressin, and has comparable pharmacodynamic but different pharmacokinetic properties. Vasopressin mediates vasoconstriction via V1 receptor activation on vascular smooth muscle. Septic shock first causes a transient early increase in blood vasopressin concentrations; these concentrations subsequently decrease to very low levels as compared with those observed with other causes of hypotension. Infusions of 0.01-0.04 U/min vasopressin in septic shock patients increase plasma vasopressin concentrations. This increase is associated with reduced need for other vasopressors. Vasopressin has been shown to result in greater blood flow diversion from nonvital to vital organ beds compared with adrenaline (epinephrine). Of concern is a constant decrease in cardiac output and oxygen delivery, the consequences of which in terms of development of multiple organ failure are not yet known. Terlipressin (one or two boluses of 1 mg) has similar effects, but this drug has been used in far fewer patients. Large randomized clinical trials should be conducted to establish the utility of these drugs as therapeutic agents in patients with septic shock.
Figures


Similar articles
-
Vasopressin and terlipressin in neonates and children with refractory septic shock.Curr Drug Metab. 2013 Feb;14(2):186-92. Curr Drug Metab. 2013. PMID: 23439212 Review.
-
Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.Crit Care. 2009;13(4):R130. doi: 10.1186/cc7990. Epub 2009 Aug 10. Crit Care. 2009. PMID: 19664253 Free PMC article. Clinical Trial.
-
[Indications of vasopressin in the management of septic shock].Ann Fr Anesth Reanim. 2003 Jul;22(7):600-8. doi: 10.1016/s0750-7658(03)00210-7. Ann Fr Anesth Reanim. 2003. PMID: 12946492 Review. French.
-
Arginine vasopressin vs. terlipressin in the treatment of shock states.Best Pract Res Clin Anaesthesiol. 2008 Jun;22(2):359-68. doi: 10.1016/j.bpa.2008.03.005. Best Pract Res Clin Anaesthesiol. 2008. PMID: 18683481 Review.
-
Terlipressin: vasopressin analog and novel drug for septic shock.Ann Pharmacother. 2006 Dec;40(12):2170-7. doi: 10.1345/aph.1H373. Epub 2006 Dec 5. Ann Pharmacother. 2006. PMID: 17148649 Review.
Cited by
-
The effects of terlipressin on regional hemodynamics and kidney function in experimental hyperdynamic sepsis.PLoS One. 2012;7(2):e29693. doi: 10.1371/journal.pone.0029693. Epub 2012 Feb 15. PLoS One. 2012. PMID: 22355305 Free PMC article.
-
Vasopressin in Pediatric Critical Care.J Pediatr Intensive Care. 2016 Dec;5(4):182-188. doi: 10.1055/s-0036-1583282. Epub 2016 May 9. J Pediatr Intensive Care. 2016. PMID: 31110903 Free PMC article. Review.
-
Recent advances in sepsis and septic shock.Indian J Pediatr. 2008 Aug;75(8):821-30. doi: 10.1007/s12098-008-0154-y. Epub 2008 Sep 4. Indian J Pediatr. 2008. PMID: 18769894 Review.
-
Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.Crit Care Med. 2009 Feb;37(2):666-88. doi: 10.1097/CCM.0b013e31819323c6. Crit Care Med. 2009. PMID: 19325359 Free PMC article.
-
Efficacy and Safety of Vasopressin and Terlipressin in Preterm Neonates: A Systematic Review.Int J Environ Res Public Health. 2022 Oct 22;19(21):13760. doi: 10.3390/ijerph192113760. Int J Environ Res Public Health. 2022. PMID: 36360641 Free PMC article.
References
-
- Okamura T, Toda M, Ayajiki K, Toda N. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res. 1997;34:464–472. - PubMed
-
- Landry DW, Levin HR, Gallant EM, Ashton RC, Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125. - PubMed
-
- Laszlo FA, Laszlo F, Jr, De Wield D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991;43:73–108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical